Pregnant women living with HIV (PWLHIV) are increasingly receiving dolutegravir (DTG) worldwide and in Botswana. Few studies have assessed fetal biometry in PWLHIV on DTG-based antiretroviral therapy (ART).
We evaluated fetal biometry via ultrasound in PWLHIV and HIV-uninfected (HIV-U) pregnant women enrolled in the Tshilo Dikotla cohort in Botswana. PWLHIV enrolled between 16-36 weeks gestational age (GA) and received tenofovir + emtricitabine and either DTG or efavirenz (EFV). Pregnancies with multiple gestations or ending in fetal demise were excluded. Head circumference (HCZ), biparietal diameter (BPDZ), abdominal circumference (ACZ), and femur length (FLZ) Z scores were calculated using Intergrowth-21st references. Linear regression models were fit to assess the association of in utero HIV/ART exposure with each fetal biometric Z score, and among PWLHIV, the association of DTG vs EFV exposure with fetal biometry.
Of 435 pregnant women, 176 received DTG-based ART, 92 efavirenz (EFV)-based ART, and 167 were HIV-U. PWLHIV were older (28.9 vs 24.5 years, p=<0.01) higher in gravidity (3 vs 1, p<0.01), and less likely to have completed tertiary education (9.3% vs 31.1%, p<0.01) than HIV-U women. GA at ultrasound was higher in PWLHIV than HIV-U women (28 vs 26 weeks, p=0.01). Among PWLHIV, women on DTG were younger (28.2 vs 30.5 years, p=0.01) with shorter ART duration prior to ultrasound (15.3 vs 27.6 weeks, p<0.01) than those on EFV. In unadjusted analyses, median HCZ, BPDZ, ACZ, and FLZ did not differ between fetuses of PWLHIV vs HIV-U women (-0.30 vs -0.26, p=0.15; 0.09 vs 0.07, p=0.22; 0.00 vs 0.00, p=0.57 and 1.45 vs 1.24, p=0.22 respectively). This relationship persisted after adjusting for maternal age, height, education level, gravidity and alcohol use in pregnancy. There were no differences in fetal biometry between fetuses exposed to DTG vs EFV (HCZ: -0.39 vs -0.62, p=0.15, BPD: 0.14 vs 0.34, p=0.27, ACZ: 0.31 vs 0.34, p=0.15, FLZ: 1.42 vs 1.49, p=0.24). This relationship remained after adjusting for the same variables above as well as CD4 count. (Table)
In this small Botswana cohort, there does not appear to be a substantial association between in utero HIV/ARV exposure and fetal biometry or between in utero DTG vs EFV exposure and fetal biometry. While these results are reassuring and support continued use of these regimens in pregnancy, larger studies with serial ultrasounds are needed to validate these findings.